HIV Integrase

BMS-707035 is an HIV-1 integrase (IN) inhibitor. HIV-1 integrase (IN) represents a therapeutically advantageous viral target to treat HIV/AIDS in the clinic.

Elvitegravir (GS-9137) is a potent inhibitor of the strand-transfer step of integration mediated by human immunodeficiency virus type 1 (HIV-1) integrase.

Raltegravir (MK-0518) targets integrase, an HIV enzyme that integrates the viral genetic material into human chromosomes, a critical step in the pathogenesis of HIV.

Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV.

S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones.

MK-2048 is a second generation integrase inhibitor, intended to be used against HIV infection.

HIV-1 integrase inhibitor is uesful for anti-HIV.

HIV-1 integrase inhibitor 2, in the treatment of human immunodeficiency virus (HIV) infection.

Saquinavir mesylate is an HIV Protease Inhibitor used in antiretroviral therapy.

GSK1265744 (GSK744) is a potential inhibitor of HIV integrase with IC50 value of 3 nM

GSK744 is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.

BI 224436 is a novel HIV-1 non-catalytic-site integrase inhibitor; has antiviral EC50s of <15 nM against different HIV-1 laboratory strains and cellular cytotoxicity of >90 μM.

Dolutegravir sodium is a HIV integrase inhibitor(IC50= 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

Bictegravir, also known as GS-9883, is a potent, unboosted, once-Daily HIV-1 Integrase Strand Transfer Inhibitor (INSTI) (IC50 - 1.6 nM) with improved pharmacokinetics and in vitro resistance profile.

HIV-1 integrase inhibitor 4 is a HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 3.7 nM.

HIV-1 integrase inhibitor 3 is a HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 2.7 nM.

Dolutegravir is an integrase inhibitor developed for the treatment of human immunodeficiency virus (HIV)-l infection.

Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection.

Equisetin is an N-methylserine-derived acyl tetramic acid that functions as a potent HIV integrase inhibitor. It specifically interferes with the activity of HIV-1 integrase and demonstrates notable inhibition of 11β-HSD1 and Dnp-stimulated ATPase, with an IC50 of approximately 8 nmol per mg of protein. Additionally, Equisetin exhibits significant antibacterial properties, anti-inflammatory effects, and potential benefits in managing lipid-associated disorders while also showcasing cytotoxic activity. This compound is valuable for research applications focused on HIV treatment and the exploration of antimicrobial and anti-inflammatory mechanisms.

Lepetegravir is a potent HIV integrase inhibitor that exerts its antiviral effects by blocking the integration of viral DNA into the host genome. With an EC50 value of 0.98 nM in MT-4 cells, it demonstrates strong efficacy in suppressing HIV replication. Lepetegravir is applicable in research aimed at understanding HIV pathogenesis and developing antiretroviral therapies.

PF-4776548 is a potent inhibitor of HIV integrase, a crucial enzyme in the integration of viral DNA into the host cell genome. By blocking this integration process, PF-4776548 demonstrates significant potential in the study of HIV replication and the mechanisms of AIDS pathogenesis. This compound is valuable for research applications aimed at developing antiviral strategies and understanding HIV-related diseases.

His-Cys-Lys-Phe-Trp-Trp is an HIV integrase inhibitor, exhibiting an IC50 of 2 μM. This compound impedes the integrase enzyme's function, thereby preventing viral DNA integration into the host genome. His-Cys-Lys-Phe-Trp-Trp is valuable for research focused on HIV pathogenesis and the development of antiretroviral therapies.

L-870812 is an HIV integrase inhibitor that targets the strand transfer mechanism of HIV-1 integration. This compound effectively blocks both cell-free and cell-associated HIV-1 infections, demonstrating activity against subtype C and CRFO2_AG primary isolates. L-870812 is suitable for research applications involving replication-deficient HIV-1 Ba-L (env) pseudovirus, facilitating studies aimed at understanding HIV biology and developing therapeutic strategies.